FDA Commissioner Marty Makary, M.D., has made his pick for the next director of the FDA’s Center for Drug Evaluation and ...

As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...

AstraZeneca is raising its defense against Johnson & Johnson in a fierce competition in EGFR-mutated non-small cell lung ...

The prospect of Lundbeck and Otsuka’s Rexulti becoming part of a new treatment for post-traumatic stress disorder (PTSD) ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

World IVF Day is celebrated every year on July 25 in honor of the day the first baby was born via in vitro fertilization in ...

Since starting operations in North Carolina 30 years ago, Biogen has spent approximately $10 billion to bolster its ...

ZoomRx surveyed 57 neurologists in the U.S. this month, revealing that no single drug brand holds more than 5% of top-of-mind ...

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...